SCHEMBL4879810

SCHEMBL4879810

C=CCOc1cc(CCl)ccc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
PPARG P37231 1/20 0.56
PPARD Q03181 1/20 0.56
PPARA Q07869 1/20 0.56
CYP2D6 P10635 1/20 0.50
POLB P06746 2/20 0.49
TTR P02766 2/20 0.49
KDM4E B2RXH2 5/20 0.48
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP3A4 P08684 1/20 0.47
ALOX5 P09917 1/20 0.47
AR P10275 1/20 0.47
PTGS1 P23219 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
PDE4B Q07343 4/20 0.46
PDE4A P27815 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
CA2 P00918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2846385 0.85 ALDH1A1 (0.77) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL4877099 0.84 ALDH1A1 (0.56) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL10371413 0.83 KDM4E (0.70) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL18244599 0.83 ALDH1A1 (0.63) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL3065052 0.82 MAPT (0.41) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL4523312 0.82 GAA (0.41) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL16141745 0.81 ALDH1A1 (0.54) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL185845 0.80 CA2 (0.68) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL30074670 0.80 CA2 (0.68) ALDH1A1PPARGPPARDPPARACYP2D6
SCHEMBL2523355 0.80 GAA (0.45) ALDH1A1PPARDTTRHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10822349-B2 Macrocyclic purines for the treatment of viral infections Janssen Sciences Ireland Unlimited Company (IE) 2020-11-03 US disclosed
US-20190330234-A1 MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2019-10-31 US disclosed
US-10280180-B2 Macrocyclic purines for the treatment of viral infections JANSSEN SCIENCES IRELAND UC (IE) 2019-05-07 US disclosed
EP-2872515-B1 MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN SCIENCES IRELAND UC (IE) 2016-06-08 EP disclosed
US-20150299221-A1 MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS Janssen Sciences Ireland Unlimited Company (IE) 2015-10-22 US disclosed
US-20150299221-A1 MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS Janssen Sciences Ireland Unlimited Company (IE) 2015-10-22 US disclosed
CN-102791667-B Method for producing high purity aromatic methyl alcohol, and high purity aromatic methyl alcohol composition having excellent storage stability UBE INDUSTRIES 2014-11-05 CN disclosed
WO-2014009509-A1 MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS JANSSEN R&D IRELAND (IE) 2014-01-16 WO disclosed
EP-2540695-A1 METHOD FOR PRODUCING HIGH PURITY AROMATIC METHYL ALCOHOL, AND HIGH PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT STORAGE STABILITY Ube Industries, Ltd. (JP) 2013-01-02 EP disclosed
US-20120323021-A1 METHOD FOR PRODUCING A HIGH-PURITY AROMATIC METHYL ALCOHOL AND HIGH-PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT PRESERVATION STABILITY UBE INDUSTRIES, LTD. (JP) 2012-12-20 US disclosed
CN-102791667-A Method for producing high purity aromatic methyl alcohol, and high purity aromatic methyl alcohol composition having excellent storage stability UBE INDUSTRIES 2012-11-21 CN disclosed
US-20080132477-A1 Macrocyclic Compounds Useful as Bace Inhibitors NOVARTIS AG (CH) 2008-06-05 US disclosed
EP-1851208-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS Novartis AG (CH) 2007-11-07 EP disclosed
WO-2006074950-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330234-A1 MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS PNP, HPRT1, UMPS ALDH1A1 3148/4885PPARG 2289/4885PPARD 1462/4885
US-10280180-B2 Macrocyclic purines for the treatment of viral infections PNP, HPRT1, UMPS ALDH1A1 3148/4885PPARG 2289/4885PPARD 1462/4885
US-20120323021-A1 METHOD FOR PRODUCING A HIGH-PURITY AROMATIC METHYL ALCOHOL AND HIGH-PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT PRESERVATION STABILITY ALKBH5, ALKBH2, ALKBH3 ALDH1A1 186/4885PPARG 1124/4885PPARD 1326/4885
US-20150299221-A1 MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS PNP, HPRT1, UMPS ALDH1A1 3148/4885PPARG 2289/4885PPARD 1462/4885
US-20080132477-A1 Macrocyclic Compounds Useful as Bace Inhibitors BACE1, BACE2, APP ALDH1A1 2631/4885PPARG 3280/4885PPARD 2784/4885
US-10822349-B2 Macrocyclic purines for the treatment of viral infections PNP, HPRT1, UMPS ALDH1A1 3148/4885PPARG 2289/4885PPARD 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.